Physician
Chesapeake Pediatric & Adolescent Associates, PA
Chesapeake Pediatric & Adolescent Associates, PA was paid $6.58M by Medicaid between Jan 2018 and Dec 2024, across 50 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 51% of everything it billed.
33Billing provider infoCHESAPEAKE PEDIATRIC & ADOLESCENT ASSOCIATES, PA
SALISBURY, MD 21804
SALISBURY, MD 21804
33aNPI1699894857assigned 03/28/2007
33bProvider typePediatric Adolescent Medicine Physician
28Total paid$6.58M
24GClaims146,085
24DCodes billed50
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatric Adolescent Medicine Physician providers in Maryland
Rank by total paid#1 of 54
Median peer was paid$131K
This provider vs. median50×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 816 | $25K | |
| 2019 | 782 | $22K | |
| 2020 | 29,942 | $1.16M | |
| 2021 | 30,340 | $1.26M | |
| 2022 | 32,830 | $1.50M | |
| 2023 | 27,549 | $1.41M | |
| 2024incomplete | 23,826 | $1.20M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 51% | 40,397 | 34,545 | $3.36M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 10% | 5,855 | 5,149 | $686K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 8.6% | 5,391 | 5,172 | $568K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 7.1% | 4,452 | 4,272 | $468K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 6.4% | 4,380 | 3,890 | $421K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 4.7% | 2,693 | 2,571 | $308K |
| 90686 | 2.3% | 6,845 | 6,526 | $150K | |
| D1206 | Topical application of fluoride varnish | 1.6% | 4,218 | 3,476 | $102K |
| 92551 | 1.3% | 9,438 | 9,043 | $88K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,710 | 4,266 | $57K |
| 90670 | <1% | 2,022 | 1,935 | $45K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 867 | 805 | $43K |
38 more codes
| 96127 | <1% | 12,693 | $41K | |
| 96160 | <1% | 19,615 | $41K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,188 | $35K |
| 90647 | <1% | 1,178 | $26K | |
| 90723 | <1% | 1,131 | $25K | |
| 99177 | <1% | 3,159 | $15K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 916 | $11K |
| 99173 | <1% | 3,958 | $8K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 360 | $8K |
| 90677 | <1% | 328 | $8K | |
| 90651 | <1% | 368 | $8K | |
| 90633 | <1% | 306 | $7K | |
| 90734 | <1% | 291 | $6K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 27 | $5K |
| 96161 | <1% | 1,868 | $5K | |
| 90681 | <1% | 170 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 79 | $4K |
| 94760 | <1% | 2,387 | $3K | |
| 87807 | <1% | 312 | $3K | |
| 93786 | <1% | 133 | $3K | |
| 90381 | <1% | 16 | $2K | |
| 99381 | <1% | 13 | $1K | |
| 99070 | <1% | 558 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 85 | $1K |
| 99051 | <1% | 449 | $963.16 | |
| 90715 | <1% | 42 | $931.20 | |
| 90698 | <1% | 40 | $931.20 | |
| 90710 | <1% | 14 | $325.92 | |
| 90696 | <1% | 14 | $325.92 | |
| 90700 | <1% | 12 | $279.36 | |
| 94664 | <1% | 16 | $112.00 | |
| 81003 | <1% | 132 | $107.36 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 83 | $34.87 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 33 | $21.00 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 617 | $6.30 |
| 99072 | 0% | 133 | $0.00 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | 0% | 14 | $0.00 |
| 99000 | 0% | 79 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWATSON, KIM (OPERATIONS COORDINATOR)